uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of “Moderate Buy” by Analysts

uniQure N.V. (NASDAQ:QURE) has received an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $64.1667.

A number of equities research analysts have commented on the company. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright upped their price objective on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Royal Bank Of Canada increased their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Finally, Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research note on Wednesday, June 17th.

uniQure Price Performance

Shares of QURE stock opened at $42.63 on Monday. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -12.25 and a beta of 0.90. uniQure has a one year low of $8.73 and a one year high of $71.50. The company’s fifty day moving average price is $33.03 and its 200-day moving average price is $24.56. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Sell-side analysts expect that uniQure will post -3.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 164,429 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. This trade represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 433,229 shares of company stock worth $17,944,799 over the last ninety days. 4.65% of the stock is owned by company insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Torren Management LLC purchased a new stake in uniQure in the 4th quarter worth $28,000. IFP Advisors Inc purchased a new position in shares of uniQure during the fourth quarter valued at about $48,000. Smartleaf Asset Management LLC purchased a new position in shares of uniQure during the fourth quarter valued at about $48,000. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure during the third quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.